Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Combined Phase I Dose-escalation and Phase IIa Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Immunogenicity of GLS-5310 DNA Vaccine, Administered Intradermally Against SARS-CoV-2 in Healthy Adults

NCT04673149 is registered in ClinicalTrials.gov with GeneOne Life Science, Inc. as lead sponsor.

NCT NCT04673149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04673149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Combined Phase I Dose-escalation and Phase IIa Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Immunogenicity of GLS-5310 DNA Vaccine, Administered Intradermally Against SARS-CoV-2 in Healthy Adults
Lead sponsor
GeneOne Life Science, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2020
Completion date
May 10, 2023
Enrollment
171 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2